Olema, Novartis ink another agreement, this time for a late-stage breast cancer trial

Katherine Lewin

News Reporter

Olema Oncology is again teaming up with Novartis, with the companies partnering on a new clinical trial collaboration and supply agreement for an investigational breast …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Olema, Novartis ink another agreement, this time for a late-stage breast cancer trial

Katherine Lewin

News Reporter

Sign up to read this article for free.

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Novocure says electric field therapy extends life for pancreatic cancer patients by two months

Ole­ma, No­var­tis ink an­oth­er agree­ment, this time for a late-stage breast can­cer tri­al

Katherine Lewin

News Reporter

Sign up to read this article for free.

more like this

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

Merus drug shows ‘un­ex­pect­ed im­prove­ment’ in sec­ond-line head and neck can­cer study

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Novo­cure says elec­tric field ther­a­py ex­tends life for pan­cre­at­ic can­cer pa­tients by two months

Olema, Novartis ink another agreement, this time for a late-stage breast cancer trial

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Novocure says electric field therapy extends life for pancreatic cancer patients by two months